RNA Processing Modification Mediated Subtypes Illustrate the Distinctive Features of Tumor Microenvironment in Hepatocellular Carcinoma

Overview

Journal Genes Immun

Date 2024 Mar 13

PMID 38472339

Authors

Xinhui Li

Shan Liu

Laibin Zou

Min Dai

Chaobei Zhu

Affiliations

Soon will be listed here.

Abstract

Multiple transcript isoforms of genes can be formed by processing and modifying the 5' and 3' ends of RNA. Herein, the aim of this study is to uncover the characteristics of RNA processing modification (RPM) in hepatocellular carcinoma (HCC), and to identify novel biomarkers and potential targets for treatment. Firstly, integrated bioinformatics analysis was carried out to identify risk prognostic RPM regulators (RPMRs). Then, we used these RPMRs to identify subtypes of HCC and explore differences in immune microenvironment and cellular function improvement pathways between the sub-types. Finally, we used the principal component analysis algorithms to estimate RPMscore, which were applied to 5 cohorts. Lower RPMscore among patients correlated with a declined survival rate, increased immune infiltration, and raised expression of immune checkpoints, aligning with the "immunity tidal model theory". The RPMscore exhibited robust, which was validated in multiple datasets. Mechanistically, low RPMscore can create an immunosuppressive microenvironment in HCC by manipulating tumor-associated macrophages. Preclinically, patients with high RPMscore might benefit from immunotherapy. The RPMscore is helpful in clustering HCC patients with distinct prognosis and immunotherapy. Our RPMscore model can help clinicians to select personalized therapy for HCC patients, and RPMscore may act a part in the development of HCC.

References

Yang J, Hainaut P, Gores G, Amadou A, Plymoth A, Roberts L . A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019; 16(10):589-604. PMC: 6813818. DOI: 10.1038/s41575-019-0186-y. View

Sangro B, Sarobe P, Hervas-Stubbs S, Melero I . Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021; 18(8):525-543. PMC: 8042636. DOI: 10.1038/s41575-021-00438-0. View

Llovet J, Castet F, Heikenwalder M, Maini M, Mazzaferro V, Pinato D . Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2021; 19(3):151-172. DOI: 10.1038/s41571-021-00573-2. View

Zhu A, Finn R, Edeline J, Cattan S, Ogasawara S, Palmer D . Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; 19(7):940-952. DOI: 10.1016/S1470-2045(18)30351-6. View

Yavuz B, Hasanov E, Lee S, Mohamed Y, Curran M, Koay E . Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021; 8:1195-1207. PMC: 8478438. DOI: 10.2147/JHC.S322289. View

Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, Garcia-Criado A . Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. 2018; 101:72-81. DOI: 10.1016/j.ejrad.2018.01.025. View

Reyes A, Huber W . Alternative start and termination sites of transcription drive most transcript isoform differences across human tissues. Nucleic Acids Res. 2017; 46(2):582-592. PMC: 5778607. DOI: 10.1093/nar/gkx1165. View

Gruber A, Zavolan M . Alternative cleavage and polyadenylation in health and disease. Nat Rev Genet. 2019; 20(10):599-614. DOI: 10.1038/s41576-019-0145-z. View

Tan S, Zhang M, Shi X, Ding K, Zhao Q, Guo Q . CPSF6 links alternative polyadenylation to metabolism adaption in hepatocellular carcinoma progression. J Exp Clin Cancer Res. 2021; 40(1):85. PMC: 7923339. DOI: 10.1186/s13046-021-01884-z. View

10.

Chen S, Zhu Z, Yang X, Liu L, He Y, Yang M . Cleavage and Polyadenylation Specific Factor 1 Promotes Tumor Progression Alternative Polyadenylation and Splicing in Hepatocellular Carcinoma. Front Cell Dev Biol. 2021; 9:616835. PMC: 7969726. DOI: 10.3389/fcell.2021.616835. View

11.

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

12.

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

13.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

14.

Finotello F, Trajanoski Z . Quantifying tumor-infiltrating immune cells from transcriptomics data. Cancer Immunol Immunother. 2018; 67(7):1031-1040. PMC: 6006237. DOI: 10.1007/s00262-018-2150-z. View

15.

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

16.

Aran D, Hu Z, Butte A . xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017; 18(1):220. PMC: 5688663. DOI: 10.1186/s13059-017-1349-1. View

17.

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

18.

Su Y, Huang J, Hu J . mA RNA Methylation Regulators Contribute to Malignant Progression and Have Clinical Prognostic Impact in Gastric Cancer. Front Oncol. 2019; 9:1038. PMC: 6813557. DOI: 10.3389/fonc.2019.01038. View

19.

Wang X, Zhang S, Han K, Wang L, Liu X . Induction of Apoptosis by Matrine Derivative ZS17 in Human Hepatocellular Carcinoma BEL-7402 and HepG2 Cells through ROS-JNK-P53 Signalling Pathway Activation. Int J Mol Sci. 2022; 23(24). PMC: 9783520. DOI: 10.3390/ijms232415991. View

20.

Chen Q, Zheng W, Guan J, Liu H, Dan Y, Zhu L . SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma. Cell Death Differ. 2022; 30(1):137-151. PMC: 9883449. DOI: 10.1038/s41418-022-01051-7. View